Varicella-Zoster Virus Vaccine News This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Doctors urge shingles vaccine to be used in arthritis patients
Researchers at Oregon Health and Science University found that the live varicella-zoster, or shingles, vaccine boosts the immune response in arthritis patients. (Source: Health News - UPI.com)
Source: Health News - UPI.com - August 28, 2017 Category: Consumer Health News Source Type: news

Studies reveal how shingles vaccine should be used in arthritis patients
(Wiley) New research indicates that the live varicella-zoster vaccine -- which is given to protect against shingles -- elicits robust immune responses in patients when administered several weeks prior to the start of treatment with the arthritis drug tofacitinib. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 28, 2017 Category: International Medicine & Public Health Source Type: news

Notes from the Field: Hospital Contact Investigation for a Patient Who Developed a Zoster Vaccine –Related Rash — Maryland, February 2015
(Source: CDC Morbidity and Mortality Weekly Report)
Source: CDC Morbidity and Mortality Weekly Report - July 20, 2017 Category: American Health Source Type: news

Shingles Vaccination: Why Wait?
ACIP recommends the zoster vaccine be given at age 60 years. That could be too late for some. And, what about this 60-year-old? (Source: ConsultantLive)
Source: ConsultantLive - July 14, 2017 Category: Internal Medicine Authors: Terry Brenneman, MD Tags: Vaccines Source Type: news

Analysis Strengthens Herpes Zoster Link With Stroke, MI Analysis Strengthens Herpes Zoster Link With Stroke, MI
More research is needed to elucidate the effect of antiviral-agent use or vaccination on cardiovascular outcomes after herpes zoster infection, the authors said.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 11, 2017 Category: Consumer Health News Tags: Cardiology News Source Type: news

I Got Shingles As A Healthy 34-Year-Old, And It Was The Worst Pain I've Ever Felt
By Amanda MacMillan A few weeks after my 34th birthday, my husband and I went for a Saturday hike — a weekly ritual we’d started after moving to New York State’s Catskill Mountains region a few months earlier. I’d been feeling a bit under the weather, and I hoped the fresh autumn air would do me good. It didn’t. Later that night, I had chills and my skin felt strangely sensitive, like when you’re coming down with the flu. On top of that, it felt like I had pulled a muscle in my back or chest; when I breathed or stretched certain ways, I’d get shooting pains across my body. I blamed...
Source: Healthy Living - The Huffington Post - May 4, 2017 Category: Consumer Health News Source Type: news

AAFP: Educational Videos Created to Boost Adult Vaccine Uptake
New videos focus on influenza, zoster, and pneumococcal vaccine uptake among adults (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - April 15, 2017 Category: Respiratory Medicine Tags: Family Medicine, Geriatrics, Infections, Internal Medicine, Nursing, Pharmacy, Pulmonology, Institutional, Source Type: news

Zostavax
(Source: What's New at CBER)
Source: What's New at CBER - March 16, 2017 Category: Biomedical Science Source Type: news

In First Phase 3 Trial, Merck ’s Investigational Inactivated Varicella Zoster Virus Vaccine (V212) Reduced the Incidence of Confirmed Herpes Zoster Cases by an Estimated 64 Percent in Immunocompromised Subjects
Dateline City: KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first Phase 3 study results for V212, the company ’s investigational inactivated varicella zoster virus vaccine (VZV) for the prevention of herpes zoster or HZ, also known as shingles, in immunocompromised patients.Language: EnglishContact: MerckMedia:Pamela Eisele, 267-305-3558orSkip Irvine, 267-305-0338orInvestors:Amy Klug, 908-740-1898orMichael DeCarbo, 908-740-1807Ticker Slug:Ticker:MRKExchange:NYSE @Merckread ...
Source: Merck.com - Research and Development News - February 24, 2017 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK MSD NYSE:MRK Source Type: news

Why Skipping Vaccines Is A Public, Not Personal, Health Choice
(Reuters Health) - Too many U.S. adults are not getting vaccinated, putting themselves and others at risk, immunization experts say. According to the latest available data, about 44 percent of adults over age 19 had a flu shot; 20 percent had a TDAP vaccine, which protects against tetanus, diphtheria and pertussis; and 20 percent of 19-to-64-year-olds at risk of pneumonia had that vaccine (compared to 60 percent of those over 65). Just 27 percent of those over age 60 were vaccinated against herpes zoster, which cuts the risk of shingles in half, according to new guidelines from the Advisory Committee on Immunization P...
Source: Science - The Huffington Post - February 8, 2017 Category: Science Source Type: news

Herpes zoster (shingles) immunisation programme 2015 to 2016: evaluation report
This report is an evaluation of the third year of the shingles vaccination programme. It highlights the lower coverage achieved in the routine and catch-up cohort in 2015-16 compared with previous years. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - December 2, 2016 Category: Consumer Health News Source Type: news

GSK Announces EU Regulatory Submission of Candidate Vaccine for Prevention of Shingles
GlaxoSmithKline plc (LSE/NYSE: GSK) has announced the regulatory submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking approval for its candidate shingles vaccine, ShingrixTM, for the prevention of herpes zoster (shingles) in people aged 50 years or over. (Source: World Pharma News)
Source: World Pharma News - November 28, 2016 Category: Pharmaceuticals Tags: Featured GlaxoSmithKline Business and Industry Source Type: news

Shingles vaccination not at goal levels for U.S. seniors
(Reuters Health) – Just one in five people over age 60 in the U.S. have been vaccinated against a painful eruption of herpes zoster, also known as shingles, despite recommendations that all of them should get the shot. (Source: Reuters: Health)
Source: Reuters: Health - November 24, 2016 Category: Consumer Health News Tags: healthNews Source Type: news

Recombinant Zoster Vaccine Works Well in Older Patients (FREE)
By Abigail Zuger, MD Dr. Zuger is an associate editor with NEJM Journal Watch General Medicine, from which this story was adapted. Full coverage is available to subscribers at the link below.A new two-dose recombinant zoster vaccine was 90% efficacious among adults older than 70 in an industry-supported, randomized trial published in the New … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - September 14, 2016 Category: Primary Care Source Type: news

Investigational zoster vaccine effective, safe after age 70
The herpes zoster subunit vaccine was effective and safe for adults aged 70 and older in a phase III manufacturer-sponsored clinical trial, which was reported online in the New England Journal of Medicine. The ZOE-70 study (Zoster Efficacy Study in Adults 70 years of Age or Older) assessed an... (Source: Skin and Allergy News)
Source: Skin and Allergy News - September 14, 2016 Category: Dermatology Source Type: news